CSTL (Castle Biosciences) Total Receivables: $42.3 Mil (As of Mar. 2026)


CSTL Castle Biosciences Inc CSTL
73 GF Score
Price $24.51
GF Value $29.16
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Total Receivables?

Castle Biosciences CSTL +1.22% 73 Total Receivables is $42.3 Mil as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 73/100 and a GF Value™ of $29.16 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Castle Biosciences's Total Receivables for the quarter that ended in Mar. 2026 was $42.3 Mil.

Castle Biosciences Total Receivables Related Terms

Castle Biosciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences Total Receivables Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only 17.28 23.48 38.30 51.22 43.38

Castle Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.35 52.31 49.48 43.38 42.26
CSTL
73GF Score
Castle Biosciences Inc CSTL
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $42.3 Mil mean?
Castle Biosciences (CSTL) has a Total Receivables of $42.3 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Castle Biosciences and its competitors.
Is Castle Biosciences' Total Receivables too high?
Castle Biosciences' current Total Receivables is $42.3 Mil. Overall, Castle Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Total Receivables compare to FLGT and MYGN?
Castle Biosciences' Total Receivables of $42.3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Total Receivables is $42.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.16, compared to a current price of $24.51 — trading 16% below its estimated fair value. The current Total Receivables is $42.3 Mil. Castle Biosciences' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Total Receivables is $42.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $24.51 is trading 16% below its estimated GF Value™ of $29.16. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • Total Receivables: $42.3 Mil
  • GF Value™: $29.16 vs. price of $24.51 (16% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
73GF Score

Get the complete analysis for CSTL

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.51
Price
$29.16
GF Value